GLP-1 Weight-Loss Providers Ranked for 2026: FormBlends Tops List as Compounding Rules Tighten Nationwide
As brand-name GLP-1 shortages officially end and the FDA narrows the rules on compounded semaglutide and tirzepatide, a new health-desk review ranks the telehealth providers patients turn to for these treatments, spotlighting which platforms pair access with real physician oversight.
The distinction matters more in 2026 than ever. Wegovy, Ozempic, Zepbound and Mounjaro are FDA-approved finished drugs tested in large clinical trials. Compounded semaglutide and tirzepatide, made by licensed pharmacies for individual patients, are not FDA-approved and have not been FDA-reviewed for safety, effectiveness or quality. Since the FDA removed both drugs from its shortage list (tirzepatide in late 2024, semaglutide in February 2025), pharmacies can no longer mass-produce copies simply because the brand is scarce; compounding is now limited to documented, individual clinical need under section 503A.
Against that backdrop, reviewers evaluated providers on six factors: real clinician evaluation, licensed pharmacy sourcing, honesty about FDA status, accurate handling of trial evidence, compliance with post-shortage rules, and follow-up care after purchase.
The ranking
- FormBlends , Top pick. Requires a licensed physician consultation before any prescription, sources from 503A pharmacies following USP <797>/<800> standards, and states plainly that compounded medications aren’t FDA-approved. Offers ongoing follow-up rather than a one-time transaction.
- HealthRX.com , Close second, with the same clinician-first intake and licensed pharmacy sourcing; ranking gap comes down to state availability, not fundamentals.
- MeriHealth.com , Same supervised-access model, with added context for conditions like PCOS or menopause-related metabolic changes; newer platform still expanding state by state.
- WomenRX.com , Matches the licensed-clinician, licensed-pharmacy standard with a women’s-health framing; ranks fourth mainly due to a shorter track record.
- Ro , A mainstream telehealth competitor whose strength is steering patients toward FDA-approved brand drugs with insurance prior-authorization support; obesity-specific depth varies since it’s a general platform.
Why the evidence gap matters
The major trial results people cite belong to the approved brand products exactly as dosed. STEP 1 showed a 14.9% mean body-weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% on placebo. SURMOUNT-1 showed reductions up to 20.9% with tirzepatide 15 mg at 72 weeks. SURMOUNT-5, a head-to-head trial, found tirzepatide (20.2%) outperformed semaglutide (13.7%) over 72 weeks. Those numbers reflect the studied, FDA-approved products; a compounded preparation of the same molecule is not the identical, separately trialed formulation, even when properly prescribed and supervised.
Bottom line
Patients with insurance coverage for the brand product get an FDA-reviewed drug at a lower out-of-pocket cost. Those pursuing a compounded option should confirm a licensed clinician is evaluating them individually, that a licensed pharmacy is sourcing the medication, and that the provider is transparent about FDA status. Any platform that ships a vial with no evaluation, or blurs compounded and brand together, is a red flag regardless of price.
Medically reviewed by: Jayden Lea, CNS, RN
Frequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic? No. Wegovy and Ozempic are FDA-approved finished drugs, while compounded semaglutide has not been FDA-reviewed for safety, effectiveness or quality, even though it shares the same active ingredient.
Can I still get compounded GLP-1s now that the shortage is over? Sometimes. A licensed pharmacy can still compound semaglutide or tirzepatide individually under section 503A if a prescriber documents a genuine clinical need the approved product doesn’t meet; wanting a lower price alone is not sufficient justification.
Which loses more weight, brand or compounded? Trial data, including SURMOUNT-1 and STEP 1, describe results from the FDA-approved brand products dosed exactly as studied; those figures are not a guarantee for any specific compounded preparation.
References
- STEP 1 trial, semaglutide 2.4 mg weight-management study
- SURMOUNT-1 trial, tirzepatide weight-management study
- SURMOUNT-5 trial, tirzepatide vs. semaglutide head-to-head comparison
